Table 3.
Comparisons of psychopharmacological treatments between ASD+ and ASD- patients.
| ASD Measures | ||||||
|---|---|---|---|---|---|---|
| ADOS-2+ | AQ+ | |||||
| OR | C.I. | p-Value | OR | C.I. | p-Value | |
| Risperidone | 4.262−8 | −7256–−7222 | 0.996 | 2.340−8 | −5710–5675 | 0.995 |
| Aripiprazole | 19.877 | −0.504–6.483 | 0.094 | 0.611 | −3.328–2.342 | 0.733 |
| Olanzapine | 1.569 | −3.662–4.563 | 0.830 | 0.022 | −8.511–0.858 | 0.109 |
| Sertraline | 0.530 | −3.755–2.484 | 0.690 | 0.213 | −4.647–1.556 | 0.329 |
| Fluvoxamine | 0.851 | −3.069–2.746 | 0.913 | 0.235 | −4.216–1.322 | 0.306 |
| Fluoxetine | 3.943 | −2.014–4.758 | 0.427 | 179.787 | −2.186–12.569 | 0.168 |
Abbreviations: AQ = Autism Questionnaire; ADOS-2 = Autism Diagnostic Observation Schedule-2; ASD = Autism Spectrum Disorder. Note: results controlled for baseline EDI-3 Global Psychological Maladjustment (GMPC) and age.